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In this issue of the journal, there are two reports concerning the rare situation ofosteoblastic bone metastases occurring either initially or during tyrosine kinase inhibitor
(TKI) therapy in patients with advanced nonsmall cell lung cancer (NSCLC).1,2 Almost all
(34 of 38, 89%) were in patients with adenocarcinomas. One is a retrospective study of 36
patients with such metastases, the other, a brief report of two patients. Of the total of 38,
only three (8%) were active smokers. Majority (22 of 38, 58%) were women. The majority
in one study (13 of 25, 54%) had epidermal growth factor receptor (EGFR) tyrosine kinase
mutations. Combining both the studies, mutations were found more often in exon 19 (11
patients, 73%) than exon 21 (4 patients, 27%). In this regard, recent reports have shown
that patients with exon 19 deletions have a better outcome compared with the exon 21
L858R point mutation in patients receiving erlotinib.3 In both the studies, the authors
comment on the fact that the apparent progression of and to osteoblastic transformation
should not be considered prima facie evidence of progressive disease. In fact, it may well
represent excellent disease response to the TKI, either erlotinib or gefitinib. In addition,
such patients seem to have a better survival than those without osteoblastic disease. In
fact, in the larger study, those presenting with osteoblastic disease (23 patients) had a
remarkable 2-year survival rate of 31% and an overall disease-control rate of 61% (14 of
23). In addition, the initial presence of osteoblastic disease strongly suggested excellent
disease control of extraosseous sites (20 of 23, 87%). Being rare, however, it is not known
whether such patients have a better survival because of the natural history of osteoblastic
disease, because they received a TKI, or both. Also, because only the common mutations,
exons 19 and 21, were tested and that just in the larger study, it is possible that the
mutation rate of 54% (13 of 25) could be larger if other, less common, EGFR mutations
were also examined. (Ten of the 36 tumors were not tested.)
These studies raise the question of why the finding of or transformation to
osteoblastic disease is associated with a favorable outcome. Development of bone
metastases is a complex phenomenon that involves initial activation of osteoclasts that are
responsible of bone resorption and eventually of osteoblasts that synthesize the bone
matrix. The osteolytic or osteoblastic nature of the bone metastases will depend on the
prevalence of the osteoclastic or osteoblastic activity. One of us (N.N.) has previously
demonstrated that EGFR regulates bone marrow-derived mesenchymal stem cells (MSC)
secretion of cytokines, such as receptor activator of NF-kappaB ligand and M-colony-
stimulating factor, which activate osteoclasts.4 In addition, EGFR signaling has been
shown to prevent the differentiation of MSC into osteoblasts.5 We (N.N.) have also shown
that NSCLC cells secrete EGF-like peptides that can activate EGFR in MSC within the
bone metastases microenvironment, thus leading to activation of osteoclasts and inhibition
of osteoblastic differentiation.6 Interestingly, it has been recently shown that tumors
derived from NSCLC cells carrying activating mutations of EGFR express higher levels
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of EGFR ligands, amphiregulin and epiregulin as compared with
normal lung.7 Therefore, it might be hypothesized that EGFR
TKIs could act on EGFR that is expressed in MSC within the
bone microenvironment and that this phenomenon results in
inhibition of osteoclast activation, increase of osteoblastic
differentiation, and finally, the transformation to progres-
sion of osteoblastic lesions. In addition, blockade of tumor
growth might contribute to this mechanism by reducing the
ability of NSCLC cells to secrete EGFR ligands.
Importantly, however, this hypothesis does not explain
why patients who present with osteoblastic disease have a
better prognosis.8 Whether the presence of osteoblastic me-
tastases at diagnosis might be associated with lower levels of
EGFR-like peptides or to a reduced activation of EGFR
within the tumor microenvironment because of yet-not-iden-
tified genetic or epigenetic mechanisms that might be asso-
ciated with response to EGFR TKIs remains to be deter-
mined. Finally, it should be emphasized that, as per these two
articles, the appearance of new osteoblastic lesions does not
necessarily represent progressive disease; it may, in fact,
signify the presence of an activating EGFR mutation and
subsequent response to TKI therapy.
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